Overview

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Status:
Not yet recruiting

Trial end date:
2025-11-07

Target enrollment:

Participant gender:

Summary

We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 1 year.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Tirzepatide